Filling the need for trusted information on national health issues…

Trending on kff Ebola Marketplaces Consumer Resources

Kaiser Daily Global Health Policy ReportClinical Research/R&D Search Results « » The Henry J. Kaiser Family Foundation

Clinical Research/R&D

  • your selections
Clear Search

Filter Results

date

Tags

  • results
Supporting Disease Research Is ‘Legitimate And Necessary Government Function’

Richmond Times-Dispatch: An Ebola Vaccine? Editorial Board “Concern about the spread of Ebola has waned in recent weeks. It would diminish more if a vaccine existed. … NIH officials say an Ebola vaccine could be a year or two closer to fruition had funding been adequate. The claim sounds self-serving;…

More U.S., International R&D Funding Needed For Neglected Diseases, Experts Say

Humanosphere: U.S. sequester took big bite out of global research and development spending Humanosphere reporter Tom Murphy explores U.S. and international funding for global health research and development and neglected diseases. He includes comments from Mary Moran, executive director of Policy Cures; WHO Director-General Margaret Chan; and Mel Spigelman, president…

Experimental Ebola Vaccine To Enter Phase III Trials In Next Two Months, WHO Says

Reuters: Pivotal Ebola vaccine trials to start this month or next: WHO “Final-stage trials of experimental Ebola vaccines will begin in January or February in the worst-hit West African countries as scientists and drugmakers race to block the deadly disease, the World Health Organization said on Thursday…” (Nebehay, 1/8). U.N.…

GHTC Provides 10 Reasons For U.S. Policymakers To Support Global Health R&D

Global Health Technologies Coalition’s “Breakthroughs”: 10 reasons why the U.S. policymakers should support global health research and development Marissa Chmiola, GHTC’s communications officer, discusses the organization’s top 10 reasons for U.S. policymakers to support global health R&D, including that it saves lives, creates jobs, provides national security, and promotes cost-savings,…

Several Companies Working On Experimental Ebola Vaccines In Unprecedented Effort

Daily Beast: The Race for the Ebola Vaccine “…Although a few smaller companies have become involved in the race for a vaccine, three major pharmaceuticals are taking the lead — each pursuing a different vaccine. The trials are unprecedented for a variety of reasons, including the rapid timeline (trials of…

Richard Feachem Discusses Role Of Research, Policy, Private Sector In Malaria Response

Development Policy Centre’s “Devpolicy Blog”: Research, policy and the private sector: Sir Richard Feachem on malaria “…Professor Gabriele Bammer of the National Centre for Epidemiology and Population Health at ANU interviewed Sir Richard [Feachem, director of the Global Health Group at UCSF Global Health Sciences,] on the role of researchers,…

J&J Begins Human Trials Of Experimental Ebola Vaccine

Bloomberg News: J&J Injects First Volunteer in Race to Make Ebola Vaccine “Johnson & Johnson (JNJ) started a trial of its experimental Ebola vaccine in the U.K. and said it will produce two million courses of the shot this year…” (Bennett, 1/6). Reuters: J&J, Bavarian Nordic start clinical tests in…

GHIT Fund Helping Pharmaceutical Companies To Develop NTD Treatments

Japan Times: Japanese drugmakers addressing neglected tropical diseases, and not just out of altruism “…A total of one billion people are currently infected with NTDs, a major obstacle to development in poorer countries. To address the problem, the Global Health Innovative Technology (GHIT) Fund, a Japan-initiated organization, assists in the…